×
About 680 results

ALLMedicine™ Adult-onset Still's Disease Center

Research & Reviews  258 results

Disparities in the prevalence of clinical features between systemic juvenile idiopathic...
https://doi.org/10.1093/rheumatology/keac027
Rheumatology (Oxford, England); Ruscitti P, Natoli V et. al.

Jan 26th, 2022 - To compare clinical features and treatments of patients with systemic juvenile idiopathic arthritis (sIJA) and adult-onset Still's disease (AOSD). The clinical charts of consecutive patients with sJIA by International League of Association of Rheu...

New-onset Adult-onset Still's disease-like syndrome after ChAdOx1 nCoV-19 vaccination-a...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764317
Clinical Rheumatology; Padiyar S, Kamath N et. al.

Jan 19th, 2022 - We report a series of 3 Adult-onset Still's disease (AOSD)-like presentations in previously healthy females following vaccination with the ChAdOx1 nCoV-19 vaccine, and also compare them with similar cases reported in literature through a PubMed da...

Latent class analysis of 216 patients with adult-onset Still's disease.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722082
Arthritis Research & Therapy; Sugiyama T, Furuta S et. al.

Jan 5th, 2022 - Adult-onset Still's disease (AOSD) is a rare systemic autoinflammatory disease which encompasses patients with heterogenous presentation and a wide range of clinical courses. In this study, we aimed to identify potential subgroups of AOSD and reve...

Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions
https://clinicaltrials.gov/ct2/show/NCT03510442

Jan 4th, 2022 - The purpose of this protocol is to study the natural history, genetics and pathophysiology of systemic juvenile idiopathic arthritis (sJIA), adult-onset Still s disease (AOSD) and related inflammatory conditions. One of seven subtypes of juvenile ...

Treatment of Macrophage Activation Syndrome (MAS) With Anakinra
https://clinicaltrials.gov/ct2/show/NCT02780583

Jan 4th, 2022 - Macrophage activation syndrome (MAS) is a disorder whereby the immune system generates very high levels of substances (cytokines) that promote inflammation to the extent dysfunction occurs in multiple organ systems which if unchecked, is frequentl...

see more →

Clinicaltrials.gov  6 results

Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions
https://clinicaltrials.gov/ct2/show/NCT03510442

Jan 4th, 2022 - The purpose of this protocol is to study the natural history, genetics and pathophysiology of systemic juvenile idiopathic arthritis (sJIA), adult-onset Still s disease (AOSD) and related inflammatory conditions. One of seven subtypes of juvenile ...

Treatment of Macrophage Activation Syndrome (MAS) With Anakinra
https://clinicaltrials.gov/ct2/show/NCT02780583

Jan 4th, 2022 - Macrophage activation syndrome (MAS) is a disorder whereby the immune system generates very high levels of substances (cytokines) that promote inflammation to the extent dysfunction occurs in multiple organ systems which if unchecked, is frequentl...

Study of CRP, Ferritine and D-Dimer in Covid-19 Patients Admitted To Respiratory ICU in Assuit University Hospitals
https://clinicaltrials.gov/ct2/show/NCT05102695

Nov 5th, 2021 - Inflammatory markers are often elevated in patients with COVID-19, notably C-reactive protein (CRP), D-dimer, lactate dehydrogenase (LDH), IL-6and ferritin. Multiple prior studies have found correlations between various biomarkers and clinical out...

Auvergne-Rhône-Alpes-Limousin Research Database for Still's Diseases in Children and Adults
https://clinicaltrials.gov/ct2/show/NCT05055882

Sep 24th, 2021 - Adult-Onset Still's disease is a polygenic autoinflammatory disease of unknown etiology. The autoinflammatory character individualizes it from autoimmune autoantibody diseases. Clinically, it results in the classic triad associating hectic fever, ...

Canakinumab for Treatment of Adult-onset Still's Disease
https://clinicaltrials.gov/ct2/show/NCT02204293

Aug 7th, 2020 - The purpose of this trial is to investigate the efficacy of the treatment with canakinumab in participants with Adult-onset Still's Disease (AOSD) and active joint involvement.

see more →

News  8 results

NICE Recommends Anakinra for Paediatric and Adult-onset Still’s Disease
https://www.medscape.com/viewarticle/948506

Apr 1st, 2021 - The National Institute for Health and Care Excellence (NICE) has recommended anakinra (Kineret, Swedish Orphan Biovitrum) as a treatment option for Still’s disease in adults and systemic juvenile idiopathic arthritis in children. Anakinra is an in...

FDA Approves Canakinumab (Ilaris), First Drug for Adult-Onset Still's Disease
https://www.medscape.com/viewarticle/932625

Jun 19th, 2020 - The Food and Drug Administration has expanded the indications for canakinumab (Ilaris) to include all patients with active Still's disease older than 2 years, adding adult-onset Still's disease (AOSD) to a previous approval for juvenile-onset Stil...

Lethal Lung Disease and Biologics: Is There a Link?
https://www.medpagetoday.com/rheumatology/arthritis/81966

Sep 4th, 2019 - A new, potentially life-threatening parenchymal lung disease is increasingly being detected in patients with systemic juvenile idiopathic arthritis (sJIA), according to recent reports. Systemic JIA is distinct from other forms of JIA in that the a...

IL-6 for Adult Still's: A New Option?
https://www.medpagetoday.com/rheumatology/generalrheumatology/75699

Oct 14th, 2018 - Action Points Some clinical benefits were seen among patients with adult-onset Still's disease treated with tocilizumab (Actemra) in a small clinical trial, but the study's primary endpoint was not met. During the double-blind part of the trial, t...

Blocking IL-18 Shows Promise in Still's Disease
https://www.medpagetoday.com/rheumatology/arthritis/71381

Feb 26th, 2018 - Targeting interleukin (IL)-18 with tadekinig alfa showed promise as a novel strategy for the treatment of refractory adult-onset Still's disease in a phase II study. Among 10 patients who received subcutaneous tadekinig alfa, 80 mg three times wee...

see more →